Lifting symptom burden - How far off the ground are we?

Supportive Care in Cancer

Volumn 16, Issue 7, 2008, Pages 757-761

  Davis, Mellar P ^a   Kirkova, Jordanka ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; PSYCHOSTIMULANT AGENT;

ADVANCED CANCER; ANOREXIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; DIARRHEA; DRUG INDUCED DISEASE; EDITORIAL; ESOPHAGITIS; EXERCISE; FATIGUE; FEBRILE NEUTROPENIA; HEALTH CARE COST; HUMAN; INSOMNIA; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; NAUSEA; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION INJURY; RISK BENEFIT ANALYSIS; SYMPTOMATOLOGY; VOMITING; WEAKNESS;

FATIGUE; HUMANS; NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 49949152303     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0401-1     Document Type: Editorial

References (48)

1. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 34(1):94-104. Jul
2. Cherny NI, Catane R, European Society of Medical Oncology Taskforce on Palliative and Supportive Care (2003) Attitudes of medical oncologists toward palliative care for patients with advanced and incurable cancer: report on a survey by the European Society of Medical Oncology Taskforce on Palliative and Supportive Care. Cancer 98(11):2502-2510. Dec 1
3. Cleeland CS, Reyes-Gibby CC (2002) When is it justified to treat symptoms? Measuring symptom burden. Oncology (Williston Park) 16(9 Suppl 10):64-70. Sep
4. Boyar M, Raftopoulos H (2005) Supportive care in lung cancer. Hematol Oncol Clin North Am 19(2):369-387. vii, Apr
5. Bukowski R, Cella D, Gondek K, Escudier B, Sorafenib TARGETs Clinical Trial Group (2007) Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30(3):220-227. Jun
6. Bacik J, Mazumdar M, Murphy BA, Fairclough DL, Eremenco S, Mariani T et al (2004) The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 13(1):137-154. Feb
7. Miaskowski C, Lee KA (1999) Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J Pain Symptom Manage 17(5):320-332. May
8. Cleeland CS (2007) Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 37:16-21. 2(37):16-21
9. Kirkova J, Walsh D (2007) (Sep) Cancer symptom clusters-a dynamic construct. Support Care Cancer 15(9):1011-1013
10. Gapstur RL (2007) Symptom burden: a concept analysis and implications for oncology nurses. Oncol Nurs Forum 34(3):673-680. May
11. Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ et al (2004) A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 11(5):279-292
12. Servaes P, Verhagen C, Bleijenberg G (2002) Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer 38(1):27-43. Jan
13. Visser MR, Smets EM, Sprangers MA, de Haes HJ (2000) How response shift may affect the measurement of change in fatigue. J Pain Symptom Manage 20(1):12-18. Jul
14. Gondek K, Sagnier PP, Gilchrist K, Woolley JM (2007) Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. J Clin Oncol 25(32):5087-5093. Nov 10
15. Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR (2007) Pharmacologic treatment of cancer-related fatigue. Oncologist 12(Suppl 1):43-51
16. Kallich JD, Tchekmedyian NS, Damiano AM, Shi J, Black JT, Erder MH (2002) Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park) 16(9 Suppl 10):117-124. Sep
17. Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS (2007) Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 μg every 2 weeks. Cancer 110(7):1629-1640. Oct 1
18. US Department of Health and Human Services. Patient-reported outcomes measures - use in medical product development to support labeling claims. 2006; Available at: http://www.fda.gov/cder/guidance/5460dft.pdf.
19. Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T et al (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40(7):1021-1030. May
20. Fang FM, Tsai WL, Chiu HC, Kuo WR, Hsiung CY (2004) Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 58(5):1394-1404. Apr 1
21. Monk BJ, Huang HQ, Cella D, Long HJ 3rd, Gynecologic Oncology Group Study (2005) Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23(21):4617-4625. Jul 20
22. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403-2413. Jun
23. Parliament MB, Danjoux CE, Clayton T (1985) Is cancer treatment toxicity accurately reported. Int J Radiat Oncol Biol Phys 11(3):603-608. Mar
24. Varricchio CG, Sloan JA (2002) The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer. J Natl Cancer Inst 94(16):1184-1185. Aug 21
25. Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA (2007) A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer 109(4):787-795. Feb 15
26. Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R et al (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23(10):2145-2154. Apr 1
27. Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D et al (2007) Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25(34):5374-5380. Dec 1
28. Barnes EA, Bruera E (2002) Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer 12(5):424-428. Sep-Oct
29. Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G et al (2007) Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin.Oncol 25(32):5070-5077. Nov 10
30. Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118(8):622-629. Apr 15
31. Lai JS, Cella D, Chang CH, Bode RK, Heinemann AW (2003) Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res 12(5):485-501. Aug
32. Yost KJ, Eton DT (2005) Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 28(2):172-191. Jun
33. Dahele M, Skipworth RJ, Wall L, Voss A, Preston T, Fearon KC (2007) Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. J Pain Symptom Manage 33(6):676-685. Jun
34. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23(12):2606-2617. Apr 20
35. Osoba D (1999) What has been learned from measuring health-related quality of life in clinical oncology? Eur J Cancer 35(11):1565-1570. Oct
36. Dooms CA, Pat KE, Vansteenkiste JF (2006) The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer. Expert Rev Anticancer Ther 6(4):531-544. Apr
37. Marsh S (2007) Impact of pharmacogenomics on clinical practice in oncology. Mol Diagn Ther 11(2):79-82
38. Chada S, Menander KB, Bocangel D, Roth JA, Ramesh R (2008) Cancer targeting using tumor suppressor genes. Front Biosci 13:1959-1967. Jan 1
39. Fallowfield LJ, Harper P (2005) Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer 48(3):365-377. Jun
40. Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317(7161):771-775. Sep 19
41. Hassan I, Cima RC, Sloan JA (2006) Assessment of quality of life outcomes in the treatment of advanced colorectal malignancies. Gastroenterol.Clin.North Am 35(1):53-64. Mar
42. Kaiser R (2005) Antiemetic guidelines: are they being used? Lancet Oncol 6(8):622-625. Aug
43. Nelson KA, Walsh D (2003) The business of palliative medicine-Part 3: The development of a palliative medicine program in an academic medical center. Am J Hosp Palliat Care 20(5):345-352. Sep-Oct
44. Strasser F, Sweeney C, Willey J, Benisch-Tolley S, Palmer JL, Bruera E (2004) Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. J Pain Symptom Manage. 27(6):481-491. Jun
45. Homsi J, Walsh D, Nelson KA, LeGrand SB, Davis M, Khawam E et al (2002) The impact of a palliative medicine consultation service in medical oncology. Support. Care Cancer 10(4):337-342. May
46. Walsh D, Zhukovsky DS (2004) Communication in palliative medicine: a pilot study of a problem list to capture complex medical information. Am J Hosp Palliat Care 21(5):365-371. Sep-Oct.
47. Jansman FG, Postma MJ, Brouwers JR (2007) Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 25(7):537-562
48. Garcia SF, Cella D, Clauser SB, Flynn KE, Lai JS, Reeve BB et al (2007) Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol 25(32):5106-5112. Nov 10